Elisabeth-Tweesteden Ziekenhuis — Clinical Trial Site

20 Registered trials

4 Currently recruiting

Organisation

Elisabeth-Tweesteden Ziekenhuis

Location

Tilburg, Netherlands

Identifier

ORG-100045881

Address

Dr. Deelenlaan 5, 5042 AD, Netherlands

Departments

#2911: Cardiology
#3706: Cardiology
Cardiology
Department of Internal Medicine
Department of Internal Medicine and Oncology
Department of Surgery
Interventional Cardiologist
Longgeneeskunde
Medical Oncology
N/A
Oncology

Clinical trials at this site (20)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
PERi-operative Selective Decontamination of the Digestive tract to prevent severe infectious complications after Esophagectomy: a Randomized… Recruiting

2023-504144-33-01 esophageal cancer 11 2024-10-17
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock f… Recruiting

2024-510892-40-00 Acute myocardial infarction complicated by cardiogenic 6 2024-02-29
WOEST-3 Recruiting

2022-502140-13-00 Atrial fibrillation Acute coronary syndrome Chronic cor 6 2023-01-11
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
ARTEMIS - A research study to look at how ziltivekimab works compared to placebo in people who have had a heart attack Ended

2023-506876-28-00 The medical condition we are investigating is type 1 AM 5 2024-08-01
TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended

2023-503312-32-00 Esophageal squamous cell carcinoma 4 2024-06-24
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2021-03-24
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit… Ended

2023-508292-37-00 Cardiovascular Disease 5 2020-03-06
CRITICS-II Ended

2023-503248-15-00 Patients with TNM 8th ed stage IB-IIC gastric adenocaci 4 2017-10-09
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended

2023-510159-53-01 peritoneal dissemination in stomach cancer patients 4 2017-09-28
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and… Ended

2022-502382-25-00 Heart Failure and Pulmonary Hypertension due to Left He 4 2023-08-24
Investigation to assess the effects of zalunfiban in patients with an acute heart attack Ended

2023-508485-15-00 Subjects with documented STEMI, presenting with persist 5 2021-04-22